Placental Protein 5 (Pp5) in Complicated Pregnancies

Nisbet, Alasdair J.; Bremner, R. D.; Jandial, V.; Sutherland, H. W.; Horne, C. H. W.; Bohn, H.

doi:10.1111/j.1471-0528.1981.tb01022.x

Cited by 13 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In twin pregnancy, serum levels of PP5 were elevated as reported pre viously [Nisbet et al, 1981b;Salem et al, 1982]. This finding can be attrib uted to the enlarged placental mass.…”

Section: Weeks Of Gestationsupporting

confidence: 69%

“…Salem et al [198 Id] stated that PP5 levels were often elevated prior to placental abrup tion; that is, increased PP5 concentration may be an early sign of coagula tion abnormalities at the placental site. Significantly elevated PP5 concen trations were noted in women with pre-eclampsia and maternal diabetes [Nisbet et al, 1981b;Salem et al, 198Id, 1982]. Although the number of women surveyed in this study was small, PP5 concentrations in pregnant diabetic women were within the normal range.…”

Section: Weeks Of Gestationmentioning

confidence: 75%

See 1 more Smart Citation

Circulating Levels of Placental Protein 5 in Normal and Abnormal Pregnancies

Takayama¹,

Soma²,

Saito³

et al. 1983

Gynecol Obstet Invest

View full text Add to dashboard Cite

Serum concentrations of PP5 were measured by radioimmunoassay in 219 women with normal pregnancies and 163 women whose pregnancies were complicated. PP5 in serum disappeared rapidly after delivery, with a half-life of 5–10 min in the first 10min. Serum PP5 levels were higher in uterine than in antecubital venous blood. In normal pregnancies, PP5 was detectable at 7–8 weeks of gestation; its mean concentration rose gradually to a maximum of 17.8 ± 10.2 ng/ml at 34–35 weeks of gestation. Elevated serum PP5 concentrations were noted in patients whose pregnancies were complicated by toxemia of pregnancy with appropriate-for-date baby or by twin pregnancy. Low serum PP5 concentrations tended to be found in patients whose pregnancies were complicated by abortion, intrauterine fetal death, and hydatidiform mole. Marked abnormal PP5 levels were not found in patients with maternal diabetes and placenta previa. These findings suggest that the assay of serum PP5 concentrations can be a useful parameter in determining the prognosis of abnormal pregnancies.

show abstract

“…In twin pregnancy, serum levels of PP5 were elevated as reported pre viously [Nisbet et al, 1981b;Salem et al, 1982]. This finding can be attrib uted to the enlarged placental mass.…”

Section: Weeks Of Gestationsupporting

confidence: 69%

Section: Weeks Of Gestationmentioning

confidence: 75%

Circulating Levels of Placental Protein 5 in Normal and Abnormal Pregnancies

Takayama¹,

Soma²,

Saito³

et al. 1983

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…generate a series even of this size in most fully The levels of PP5 show an elevation comparable developed countries. Furthermore, six of the to that previously reported in pre-eclampsia seven patients were multiparous which again is (Salem et al 1982;Nisbet et al 1981). The mechnot typical of the condition in other areas.…”

Section: Discussionsupporting

confidence: 60%

Circulating levels of placental proteins, placental protein 5 (PP5), placental lactogen and Schwangerschafts‐protein 1 (SP1), in antepartum eclampsia

Salem

Shaaban

Ghaneimah

et al. 1983

BJOG

View full text Add to dashboard Cite

show abstract

“…The initial observations on CRF levels in pregnancy-induced hypertension indicate that levels rise, which is like placental protein 5 (PPS) (Nisbet et al 1981) and pregnancy-associated plasma protein-A (PAPP-A) (Lin et al 1977) but unlike other placental proteins which are unchanged or decreased (Salem et al 1983;Spellacy et al 1971). It is not certain whether the rise in CRF is primary or secondary to the pregnancy-induced hypertension but CRF is a peripheral vasodilator (Fisher et al 1983) and consequently the rise may be a compensatory response to pregnancy-induced hypertension.…”

Section: Discussionmentioning

confidence: 99%

Plasma corticotrophin‐releasing factor (CRF) in abnormal pregnancy

Wolfe¹,

Patel²,

Campbell³

et al. 1988

BJOG

161

View full text Add to dashboard Cite

Summary. Maternal plasma levels of cortiocotrophin‐releasing factor (CRF) have been measured in abnormal pregnancy states to assess their potential as biochemical markers for at‐risk pregnancies. CRF levels were not significantly altered in patients with hydatidiform mole, polyhydramnios or diabetes. CRF levels were elevated in pregnancies complicated by accidental antepartum haemorrhage at 28 weeks (P<0·03) but not for the rest of the third trimester. In twin pregnancies CRF levels were significantly raised throughout the third trimester (28–32 weeks, P<0·01; 34–36 weeks, P<0·001). In patients with pregnancy‐induced hypertension (28 weeks, P<0·001; 32–36 weeks, P<0·001; and 38–40 weeks, P<0·01), preterm labour and premature rupture of the membranes (28 weeks, P<0·004; 30–32 weeks, P<0·002; and 34–36 weeks, P<0·001), CRF levels were significantly raised and in some patients levels were elevated 11 weeks before the onset of signs or symptoms. These observations raise the possibility that maternal CRF measurement may be of use as a predictive indicator of certain at‐risk pregnancies.

show abstract

Placental Protein 5 (Pp5) in Complicated Pregnancies

Cited by 13 publications

References 13 publications

Circulating Levels of Placental Protein 5 in Normal and Abnormal Pregnancies

Circulating Levels of Placental Protein 5 in Normal and Abnormal Pregnancies

Circulating levels of placental proteins, placental protein 5 (PP5), placental lactogen and Schwangerschafts‐protein 1 (SP1), in antepartum eclampsia

Plasma corticotrophin‐releasing factor (CRF) in abnormal pregnancy

Contact Info

Product

Resources

About